No multiple therapies combining FGFR inhibitors with immunotherapy (unlike in HER2-positive breast cancer - PA150–001 with pembrolizumab (NCT03514121) or afatinib together with trastuzumab and chemotherapy (NCT01594177)) have been developed yet. This evidence concerns the gene ERBB2 and breast cancer.